Venus Remedies secures five marketing approvals in four countries

Regulatory product approvalBusiness Updates View source PDF Explain this filing

VENUSREM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.7%Reaction day

₹1577.00

prior close

₹1649.50

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.7%+4.0% vs market

Pharmaceuticals peers, median of 173sector+0.0%+4.6% vs sector

On the reaction day the stock moved 4.0 pts more than Nifty Microcap 250 and 4.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.0

10m

+0.0

15m

+0.1

30m

+0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.7+0.7+4.0+0.0+4.6

Next day

+1.5-1.0+2.4-1.2+2.6

-4.0-3.6-0.4-2.8-1.1

-8.3-4.5-3.8-3.8-4.5

-10.3-6.8-3.5-5.0-5.2

-6.8-6.4-0.5-3.9-2.9

-15.3-4.7-10.6-0.9-14.4

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Venus Remedies has secured five marketing authorisations across Kazakhstan, Peru, Kuwait, and Argentina. Approvals cover Vancomycin and Fluorouracil in Kazakhstan, Fulvestrant in Peru, Methotrexate in Kuwait, and Meropenem in Argentina, spanning the CIS region, Latin America, and the Middle East. The company already operates in over 100 countries and is a leader in critical-care injectables. Management said the approvals strengthen international presence and expand access to its pharmaceutical portfolio.

Likely market impact

Positive for international growth; expands product reach across CIS, Latin America, and Middle East markets.